Contact | 
Print version | 
PDF version | 
Send article | 
RSS feed
MedImmune and Crucell jointly develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection
17 Oct 2007 -
MedImmune and Crucell N.V. announced that they have entered into an exclusive license and research collaboration to further develop and commercialize one of Crucell's panels of bacterial antibodies primarily for the treatment and prevention of hospital-acquired bacterial infection.
Under the agreement, MedImmune is to provide Crucell certain upfront, annual and milestone payments potentially exceeding US$ 40 million, plus research and development (R&D) funding and an undisclosed royalty on product sales.
Under the terms of the agreement, Crucell has granted MedImmune an exclusive license to research, develop and commercialize antibodies within one of its MAbstract®-technology programs. In addition MedImmune will have access to Crucell's antibody capabilities for further R&D.
The partnership combines Crucell's unique antibody discovery, research and development capabilities with MedImmune's expertise in clinical development and commercialization of anti-infective antibodies.
In 2005, Crucell announced the initiation of several new antibody discovery programs in the field of hospital-acquired infections. Under the terms of the license agreement announced today, Crucell has now entered into a partnership with MedImmune for one of these programs. Crucell has discovered and developed these unique anti-bacterial antibodies using its proprietary MAbstract® technology.
Top
